Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe…

Overview of attention for article published in Liver International, June 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 2 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 8,766 followers.

RT @LiverInt: Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 we…

Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis https://t.co/4wwLNDP1Ph

Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for eight weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis https://t.co/vorsK3sDCh

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.